Navigation Links
Pilot Testing Phase Ends; Expansion Of Sales Force Begins
Date:4/13/2010

PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

Whitehouse Station, NJ/Las Vegas, NV (PRWEB) April 14, 2010 -- PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

Over the past three years, the company has been promoting, on a pilot test basis, its current product line with experienced pharmaceutical-trained sales associates to physicians in selected pockets of northern New Jersey, New York City and Long Island, NY with favorable acceptance and patient outcomes. The Company has now expanded its sales effort to 16 sales associates and plans to continue its expansion to 30 sales associates by July 1st, 2010. The current sales effort is and will be focused up and down the east coast corridor from Massachusetts to Florida, and into Texas, Pennsylvania and Illinois. Expansion is planned to continue throughout 2011 with the goal to have a national sales effort within prominent high-density metropolitan Primary Care Physician areas across the country.

The Company currently promotes seven products: PreCrea® for pre-diabetes; PreLipid® and PreLipid Plus®, for lowering cholesterol naturally; PreMenora® and PreMenora®Plus, for relieving symptoms of perimenopause; and PreArthros™, and PreArthros™Plus for joint inflammation and pain, via a pharmaceutical style sales force. In addition, the Company has also developed a series of new formulations as viable all-natural alternatives for various chronic conditions, which it plans to launch over time once it has established a sufficient beachhead with its current product line with Primary Care Physicians.

Chuck Blitzer, the Company’s Chief Executive Officer stated, “We are extremely pleased with the results from our pilot testing program (which reached over 1,500 physicians and over 200,000 patient experiences) and now, our effort to formally begin building a national sales organization. Our sales associates are highly proven individuals from the pharmaceutical industry and average over 12 years of direct selling experience within the Primary Care Physician community, the largest physician audience in the country.

Our products are recommended by thousands of physicians as:

1) First-line therapy for pre-disease states, where no prescription drugs are approved,
2) An alternative for patients who are intolerant to prescription drugs or refuse to go onto a prescription drug, and
3) Additive therapy to a given prescription drug where the desired therapeutic effect of such drug has not been achieved and the physician is inclined not to increase dose.”

The Company’s financial position is sound and it hasn’t needed to raise capital since its last round of financing in 2008. It is debt free and believes it is on track to break-even by years’ end.

Dr. Joe Fenn, President and Chief Medical Officer stated “From our pilot program we learned how to promote our products effectively to Primary Care Physicians, and in every sales territory we now expand to we have doctors eager to hear our message and adopt our products as alternatives for their patients. We have also established the efficacy and safety of our products in tens of thousands of patients. ”

PreEmptive Meds, Inc., is a pre-disease focused, plant-based pharma-nutraceutical company promoting its proprietary branded products directly to the Primary Care Physician community.

###

Read the full story at http://www.prweb.com/releases/preemptivemeds/salesteam/prweb3865604.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange
2. Howard Leights New Pilot Push-in Ear Plug Delivers Occupational Hearing Protection with Innovative, Hybrid Design
3. Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges
4. Edifecs Testifies Before NCVHS Standards Subcommittee Regarding HIPAA 5010 and ICD-10 Testing
5. Doctors and Scientists Create New Society to Promote Non-Animal Toxicology Testing Methods
6. The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao
7. AXIOM Systems, Inc. Announces General Release of HIPAA 5010 Testing Solutions
8. ANY LAB TEST NOW North Dallas Lowers Diabetes Testing to $89
9. Refinement of glaucoma testing, treatment expected from US, United Kingdom study
10. Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification
11. Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pilot Testing Phase Ends; Expansion Of Sales Force Begins
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: